Exosomes or PRP for Hair Loss? What Each One Does, and Who Each One Suits

Start here: the size of the evidence gap

Most comparisons of these two treatments are written by someone who sells one of them, and they tend to land on a tidy “both are great, exosomes are newer” conclusion. We offer both, so we have no reason to steer you, and the honest version is less balanced than that.

Here is the whole picture in two numbers. A 2025 systematic review and meta-analysis in Dermatology and Therapy pooled 41 trials covering 1,877 participants on platelet-rich plasma for alopecia. A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology found the entire published human clinical evidence for exosomes in hair regeneration amounted to 11 studies and 298 patients.

That is roughly a six-to-one gap in patients studied, and it understates the difference in study quality. Of those 11 exosome studies, two were randomized. Three were retrospective, four were single-arm prospective, one was a case series, and two were case reports.

None of this makes exosomes worthless. It means anyone telling you exosomes outperform PRP for hair is ahead of the data, and it is worth knowing that before you commit to a package.

Quick comparison

	PRP	Exosome preparations
Source	Your own blood, drawn and spun during the visit	Donor-derived cell cultures produced by an outside lab
Regulatory status	Autologous blood product, performed as a procedure	No FDA-approved exosome product exists in the US
Human evidence	41 trials, 1,877 participants (2025 meta-analysis)	11 studies, 298 patients, 2 randomized (2025 review)
Typical protocol	3 to 4 monthly sessions, then every 3 to 6 months	Varies widely by provider; no standard exists
Time to visible change	Effect roughly doubles between month 3 and month 6	Reported at 3 to 6 months in single-arm studies
What drives the cost	Clinical time and session count	Product acquisition cost, then clinical time
Head-to-head trials	None published	None published

How PRP works for hair

Platelet-rich plasma is made from you. A clinician draws blood, spins it in a centrifuge to concentrate the platelets, and injects that concentrate into the scalp. Platelets carry growth factors, and the working theory is that delivering a concentrated dose of them to weakened follicles supports the growth phase.

The practical appeal is that there is no donor material and no outside manufacturer in the chain. What goes into your scalp came out of your arm forty minutes earlier. That removes an entire category of sourcing questions, which is a large part of why PRP remains the more common starting point.

What the meta-analyses actually show

The 2025 Dermatology and Therapy analysis found PRP increased hair density by a mean of 19.6 hairs per square centimeter overall, and by 28.4 hairs per square centimeter against placebo. A 2024 meta-analysis in Anais Brasileiros de Dermatologia, restricted to randomized trials in androgenetic alopecia, found a pooled increase of 27.55 hairs per square centimeter. For context, the authors of that paper noted the figure exceeded the improvement they cited for finasteride.

Patient satisfaction odds roughly doubled. Adverse events were not significantly different from control.

The part almost nobody mentions: density is not caliber

Both meta-analyses found the same thing on hair thickness. The 2025 analysis reported a mean increase of 8.2 micrometers with a confidence interval crossing zero. The 2024 analysis reported 2.02 micrometers, also crossing zero. Neither reached statistical significance, and no subgroup did.

So the honest version is that PRP puts more hairs on your head, with reasonable consistency across many trials, and does not reliably make the hairs you have thicker. Whether that reads as a win depends on what is actually bothering you when you look in the mirror.

Both analyses also carry heavy heterogeneity, with I-squared values above 93 percent, and the Brazilian group graded the evidence for density as low quality and for diameter as very low. Real effect, messy literature.

What a course looks like

Across the 43 studies in the 2025 review, 30 used monthly intervals and every one delivered PRP by intradermal injection. The American Academy of Dermatology describes the common schedule on its patient pages as monthly for three months, then every three to six months, and states plainly that PRP “is not a permanent solution.”

A 2026 review in Medical Sciences found something useful about timing. Density improvement measured at three months ranged from 8.1 to 19 hairs per square centimeter. Measured at six months it ranged from 23.1 to 49.4. The effect roughly doubles to triples in that window, which means judging your result at month three is judging it early.

One more finding worth carrying into a consultation. A 2026 analysis of 747 PRP preparations found that the number of sessions independently predicted response, with odds increasing about twofold per session. Platelet concentration did not predict response. If a clinic is selling you on how concentrated their PRP is, that is a marketing claim the data does not support.

One thing to be clear about up front, because it changes what the rest of this section means for you. Bee Well℠ does not perform microneedling. Our exosome scalp service applies the preparation following microdermabrasion, which exfoliates the surface of the scalp rather than creating channels through it.

One implication for our own service, stated plainly. Because we deliver exosomes after microdermabrasion rather than microneedling, almost none of the published hair studies used the delivery method we use. The evidence summarized above is thin to begin with, and it is less transferable to our procedure than it would be to a practice using microneedling. We would rather say that than let the research imply more than it supports.

How exosome preparations are used for hair

Exosomes are small vesicles that cells release to carry signaling material to other cells. For hair, a preparation is typically applied to the scalp after microneedling or radiofrequency microneedling, sometimes injected, on the theory that the signaling cargo supports the follicular environment.

The preparation comes from an outside lab, not from you. That makes the manufacturer, the testing, and the handling part of your decision in a way they are not with PRP. It is also why we walk every exosome patient through the fact that no exosome product is FDA-approved before anything else gets discussed.

What the 11 studies reported

Reported hair density increases ranged from 9.5 to 35 hairs per square centimeter, and hair thickness up to 13 micrometers. Adverse events were mild and transient. Those are respectable numbers on their face.

The review’s own limitations paragraph is the part to read: “Many of the studies were non-randomized, single-arm, or retrospective in nature, with a high risk of bias due to confounding and lack of blinding. Only two randomized controlled trials were identified, and these had relatively small sample sizes.”

The two randomized trials do not test what clinics sell

This is the detail that changed how we talk about exosomes for hair internally.

The first randomized trial, published in Life in 2025, enrolled 20 men and tested a plant-extract formulation built from Ecklonia cava and Thuja orientalis. That is not the mesenchymal stem cell-derived exosome injectable sold in aesthetic practices. The second appeared in a journal not indexed in PubMed or Europe PMC.

So the two pieces of randomized evidence underpinning the category test either a different product or sit outside the indexed literature. That is worth knowing before you read another article telling you the research supports exosomes for hair.

The microneedling problem

Here is a confound no competing article mentions. Microneedling on its own has randomized evidence for pattern hair loss. Almost every exosome hair study delivers the product through microneedling or radiofrequency microneedling. No published study separates what the exosomes contributed from what the needling contributed.

A 2026 systematic review in the Journal of Cosmetic Dermatology screened 256 references on microneedling with exosomes across dermatology, found eight eligible studies with sample sizes from 3 to 60, and concluded that “more evidence is required before we can ascertain the safety profile and efficacy profile of microneedling and exosomes.”

There is also a useful detail buried in a 2026 retrospective series of 20 patients using plant-derived vesicles. Ninety-five percent of patients perceived improvement. Under blinded evaluation, clinical ratings improved in 70 percent and trichoscopic measurements in only 50 percent, with 45 percent rated as stabilization or mild change. The gap between how people felt about their result and what the instrument measured is one of the more honest findings in this literature.

What should already be in place before either one

Neither of these is a first-line treatment, and a consultation that skips straight to them has skipped the part with the most evidence behind it.

Minoxidil and, for men, finasteride are the established medical therapies for pattern hair loss. They are inexpensive, they have decades of data, and they are the baseline that PRP was measured against in the meta-analyses above.

There is also biopsy evidence that they change the underlying process rather than just the appearance. A 1999 study using serial scalp biopsies found that in men on finasteride, terminal hair counts rose from 15.5 to 20.9 over twelve months while miniaturized hairs fell from 26.7 to 23.6. The authors concluded that finasteride “appears to be capable of reversing hair miniaturization in androgenetic alopecia in young to middle-aged men, but not in postmenopausal women.”

Where PRP fits is most clearly shown by a protocol study of 78 patients, all of whom had already failed at least a year of minoxidil, finasteride, or both. After six sessions, three monthly then three bimonthly, success was reported in 71.4 percent of men and 73.4 percent of women, with no change in about a fifth and worsening in roughly one in ten.

That is the honest frame. PRP performs well as an addition for people who have already tried the basics, and most of the trial population that produced its evidence base looked like that.

Women are studied less, and differently

Two meta-analyses have looked specifically at women. One pooled 21 randomized trials covering 628 participants and found PRP significantly increased hair density and thickness and reduced hairs on a pull test, with an adverse event risk ratio of 1.01. Another, covering 42 studies including 776 women, reported an odds ratio for hair density improvement of 1.61 with a confidence interval that crossed 1, which means its own numbers were less decisive than its conclusion.

There is a related signal in the male-versus-mixed data. In the 2024 randomized-trial meta-analysis, male-only studies showed a mean increase of 39.12 hairs per square centimeter while mixed-gender studies showed 7.39. That gap has not been adequately explained, and it is a reason to be more cautious about quoting male trial figures to a woman in a consultation.

When the answer is neither, and when it is surgery

There is a category of hair loss where injectables are the wrong tool, and it gets missed often enough to be worth its own section.

Scarring alopecias, including lichen planopilaris, frontal fibrosing alopecia, and discoid lupus, destroy the follicle and replace it with fibrous tissue. A 2025 systematic review covering 38 studies and 411 patients opens by describing these as conditions causing “irreversible follicular loss.” Even transplantation into scarred scalp, that review notes, tends to give good early density followed by “progressive graft loss by 3 to 5 years.”

These conditions look different from pattern loss on close examination. Loss of follicular openings, redness or scaling around the follicle, and a shifting hairline at the temples in a woman are all reasons to see a dermatologist before anyone injects anything. A biopsy may be the right next step.

We say this as a practice that sells injectables: if your scalp is smooth where hair used to be, an injectable is unlikely to be a good use of your money, and a hair restoration surgeon or a dermatologist is the right referral. We make that call regularly.

The comparison studies people will show you

Two papers get cited constantly as proof that exosomes beat PRP. Neither holds up, and you should know their names.

The first is a 2024 case series in a journal called Dermis. It compared three PRP patients, all male, mean age 29, who received five to six sessions over six to sixteen months, against two exosome patients, both female, mean age 43, who received a single session. It concluded exosomes were superior. The arms differ by sex, age, session count, and follow-up window, the total sample is five people, and the journal is not PubMed indexed.

The second is a 2025 systematic review in Cureus concluding that “exosome therapy shows the most promising results in terms of hair regrowth and safety, followed by PRP.” There are no comparative trials to synthesize, so that conclusion is not supported by comparative data. Cureus operates a pay-to-publish model with minimal peer review. In our reading, that paper is the most likely origin of the “studies show exosomes beat PRP” claim circulating online.

The one genuine head-to-head was registered in Pakistan, randomized 30 patients, and completed in July 2024. It has never reported results. Its design was also unbalanced: the exosome arm received one session, the PRP arm received two.

What actually predicts your result

Follicle status matters more than product choice, and there is old, clean data on this that almost never makes it into consumer articles.

In 1993 David Whiting published horizontal-section biopsy work on 106 men with male pattern hair loss. Among 44 patients treated with topical minoxidil, the results sorted almost entirely by how much follicular structure remained:

• Fewer than 2 follicular structures per square millimeter: no regrowth in any patient.
• Two to 4 per square millimeter: regrowth in 72 percent.
• More than 4 per square millimeter: regrowth in 86 percent.

He also found that regrowth occurred in 77 percent of cases without significant inflammation, versus 55 percent of cases with it. Inflammation cut the response rate by roughly a third.

Modern work supports the underlying picture. A landmark 2011 study in the Journal of Clinical Investigation found that bald scalp in men with pattern hair loss retains hair follicle stem cells but has markedly fewer progenitor cells. The follicle is dormant rather than gone, which is why treatment can work at all, and it sets the boundary for where it cannot.

A 2026 histopathology study adds a wrinkle worth knowing: perifollicular inflammation and fibrosis were found in 81 percent of clinically normal-appearing scalp in patients with pattern hair loss, and were more common in patients over 44, at higher Norwood grades, and in those who had responded poorly to standard therapy. In that series, roughly two-thirds of previously treatment-resistant patients improved on combined hormonal and anti-inflammatory therapy. Fibrosis is a bad prognostic sign. It is not automatically the end of the conversation.

Who tends to be a better fit for each

With all of that in hand, here is how we actually think about it.

• Early to moderate thinning, still shedding, visible miniaturized hairs. PRP is the conventional first move. The evidence base is deeper, the autologous source keeps the decision simple, and the cost per session is lower.
• Plateaued on PRP, minoxidil, or finasteride, with follicular activity still present. This is where exosome preparations get discussed most often, usually as an addition rather than a replacement, and with clear framing that the evidence is early.
• Long-standing smooth scalp with no visible follicles. Neither is likely to be a good use of your money. A surgical consultation is the more honest referral, and we make it.

Prevalence context, since almost everyone asks whether this is normal. In a population study, pattern hair loss affected 44.9 percent of men and 32.2 percent of women on an age-adjusted basis, rising to 73.5 percent of men and 57.4 percent of women over 80. Among men aged 18 to 49 in a US study, 42 percent had moderate to extensive loss.

If your hair loss started after a GLP-1 medication

This has become one of the most common reasons people call us about hair, and it changes the recommendation.

A 2026 systematic review in Science Progress screened 133 studies and included 24. Semaglutide and tirzepatide showed the highest reported incidence of hair loss among GLP-1 medications. The predominant subtypes were androgenetic alopecia and telogen effluvium, with tirzepatide, which produces the greatest weight loss, most frequently linked to telogen effluvium. Reported risk with semaglutide appeared dose-dependent, with doses under 2 mg weekly rarely implicated. Women appeared disproportionately affected. The authors were clear that causality is not established.

Telogen effluvium matters here because it behaves differently from pattern loss. It typically follows a trigger by about three months, though the range runs one to six. By definition, acute telogen effluvium lasts less than six months. Regrowth may take up to six months to restart and longer to become visible. Common triggers include crash dieting, low protein intake, iron deficiency, thyroid disease, and postpartum hormonal change.

In other words, a meaningful share of GLP-1-associated shedding is likely to resolve on its own once the trigger settles. Paying for a multi-session hair protocol to treat shedding that was going to stop anyway is a frustrating way to spend three thousand dollars.

What a workup should include first

Standard evaluation covers thyroid function, a complete blood count, serum iron, iron saturation, and ferritin. Vitamin D is worth adding: a 2026 meta-analysis of 29 studies found both ferritin and vitamin D significantly lower in telogen effluvium cases than controls, though association is not causation.

The real-world yield is high enough to justify the draw. In a retrospective review of 2,851 women with telogen effluvium, ferritin was low in 46.5 percent of those tested and iron deficiency was present in 29.5 percent.

If you are on a GLP-1 protocol with us, this conversation happens as part of the program rather than as a separate purchase.

How to know whether it worked

Hair changes slowly, memory is unreliable, and bathroom lighting is a liar. Without a baseline you will spend six months and several thousand dollars and still not know. Set one up before your first session.

Standardized photography

Same lighting, same distance, same angles, same time of day, hair dry and parted the same way. Four views at minimum: front hairline, the part line from directly above, the crown from above and behind, and one at eye level. Take them before session one, then at month three and month six.

Any practice running hair protocols should be doing this. If they are not, do it yourself. A phone on a tripod at a marked spot on the floor is enough.

Trichoscopy, if it is available

Trichoscopic imaging counts hairs per square centimeter and measures shaft diameter at a marked scalp location. It is what the trials measure, and it is the difference between knowing and believing.

Notice which one the studies rely on. In that 2026 retrospective series of plant-derived vesicles, 95 percent of patients perceived improvement, blinded clinical ratings improved in 70 percent, and trichoscopic measurements improved in only 50 percent. The further you move from measurement toward impression, the better the results look.

What to watch for, and when

• Weeks 2 to 6: possible increased shedding. This is common with several hair treatments and is not by itself a failure signal, though it is worth reporting.
• Month 3: reduced shedding is usually the first real change. Density gains at this point are typically small.
• Month 6: the honest evaluation point. Trial data shows the density effect roughly doubling to tripling between months three and six.
• Month 12: whether maintenance is holding.

Judge at month six, not month three. Decide about maintenance at month twelve. Anyone asking you to renew a package at week eight is asking before the data exists.

What a session actually involves

For PRP, expect a blood draw, roughly twenty minutes while the sample spins, topical numbing, then the injections. Most people describe them as uncomfortable rather than painful. Total appointment time runs about ninety minutes. Scalp tenderness for a day is common and most people return to normal activity the same afternoon.

Our exosome scalp service is a different procedure. There is no blood draw and no topical numbing. The scalp is prepared with microdermabrasion, a surface exfoliation, and the exosome preparation is applied afterward. Most people find it comfortable, and the visit is shorter than a PRP appointment.

We mention the logistics because hair protocols are repeat visits, not a single appointment. Three or four sessions plus maintenance means the friction of getting to a clinic is part of what determines whether people finish the course, and a meaningful number do not. Bee Well℠ runs these visits at your home or office across Dallas, Fort Worth, Frisco, and Denton, which removes the drive and the waiting room from the equation and tends to help completion rates in a practical way.

What no professional society currently says

One more thing worth knowing, because you will see it claimed in both directions.

The American Academy of Dermatology publishes no clinical guideline on androgenetic alopecia, hair loss, PRP, or exosomes. Its guideline list covers acne, atopic dermatitis, psoriasis, skin cancers, and a handful of others. What the AAD does publish are patient education pages, which describe PRP and its schedule and state that “studies show that this can be a safe and effective hair loss treatment.” Those pages do not mention exosomes at all.

The International Society of Hair Restoration Surgery has no published position statement on exosomes either. Its 2025 practice census found PRP was prescribed “always or often” by 49.8 percent of members. The census did not measure exosome adoption.

So nobody should tell you that the AAD recommends PRP or that ISHRS warns against exosomes. Neither statement exists. What does exist is the FDA’s position, which is that exosome products intended to treat conditions in humans are regulated as drugs and biological products, and that none are approved.

Worth being precise about PRP too. PRP is not FDA-approved for hair loss either. It is an autologous blood product prepared with FDA-cleared devices and used off-label, which is legal standard practice. Marketing an allogeneic exosome product as a therapy is a different legal question. That distinction is the single most commonly botched fact in this entire category.

What each one costs, and why nobody publishes a real number

No professional society, insurer, or peer-reviewed source publishes US price data for either treatment. Every figure you will find, including the ones below, is a reported range rather than a measured one, and most come from parties with something to sell.

For PRP, an aggregated patient-review site reports an average of $2,019 with a top end near $8,000, though that page has not been updated since 2023. Clinic-published pricing generally runs several hundred to roughly fifteen hundred dollars per session, with a standard three-session course commonly quoted between $1,500 and $4,000.

For exosomes, an independent editorial site reports $800 to $2,000 per session and $2,400 to $8,000 for a three to four session course. A vendor-published guide claims $2,500 to $6,000 per session. That vendor sells exosome products, which is not disqualifying but is context the page does not provide.

One thing is consistent across every source: exosomes cost more per session than PRP. The structural reason is simple. PRP has no product acquisition cost because it uses your own blood. Exosome preparations are purchased from a manufacturer, and that cost passes through with a markup.

What to ask instead of what it costs

• Is this quoted per session or for the full protocol, and how many sessions do you recommend?
• What is included, and is the consultation fee applied to treatment?
• For exosomes, who manufactures the product and will you provide the certificate of analysis for my lot?
• If I stop after two sessions, what happens to the balance?
• Does the package expire?

Compare protocol totals rather than session prices. Two quotes that look forty percent apart per session often converge once you count the sessions each one actually calls for.

Safety, honestly stated

Both treatments have good short-term safety records in the published literature, and both have reported harms worth knowing about.

For PRP, the 2025 meta-analysis found no overall difference in adverse events versus control. One subgroup finding is worth carrying into a consultation: non-activated PRP was associated with more adverse events than control, while activated PRP was not. The female-specific meta-analysis found an adverse event risk ratio of 1.01, which is as close to neutral as this kind of number gets. Expected effects are scalp tenderness, transient swelling, and occasional headache for a day.

For exosomes, the 11 clinical studies reported mild and transient effects: irritation, redness, swelling, with no serious systemic reactions. But those studies are small and mostly uncontrolled, which limits what they can detect.

Case reports have documented more. A 2026 report in Dermatologic Surgery described a persistent cutaneous reaction after facial exosome injections combined with microneedling. Two 2025 reports, both facial rather than scalp, documented granulomatous inflammation with residual scarring in four patients and ischemic tissue necrosis in another. In each case the products had been intended for topical use and were injected instead.

None of that means an exosome scalp treatment is dangerous. It means the safety picture is built on a smaller and less controlled evidence base than the PRP picture, and that handling and route matter as much as the product.

The pipeline, for context

As of August 2026, ClinicalTrials.gov lists 10 registered trials for androgenetic alopecia involving exosomes, against 26 for PRP. Most of the exosome entries are unphased, single-site, and enroll between 15 and 60 people. At least one is terminated and one carries unknown status.

The entire registered exosome-for-hair pipeline is smaller than the PRP literature that has already been published. That gap will close, and it has not closed yet.

What a good consultation covers

Before anyone quotes you a package, a consultation should establish what is driving the loss. Pattern hair loss, telogen effluvium, thyroid disease, iron deficiency, and postpartum shedding look similar in the mirror and respond very differently.

It should also involve looking closely at your scalp rather than at a price sheet. Density, miniaturization, and whether follicular openings are still visible are the variables that predict your result, and a provider who quotes a package before assessing them has skipped the part that determines whether the money is well spent.

Sometimes the honest recommendation is neither treatment. We make that call regularly, and it is the correct outcome more often than the industry likes to admit.

References

1. Anitua E, Tierno R, Alkhraisat MH. Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence. Dermatol Ther (Heidelb). 2025;15(11).
2. Kieling L, Konzen AT, Zanella RK, Valente DS. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? Anais Brasileiros de Dermatologia. 2024;99(6):847-862.
3. Al Ameer MA, Alnajim AT, Al Ameer A, et al. Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources. Clin Cosmet Investig Dermatol. 2025;18:2215-2227.
4. Gupta AK, Wang T, Welter R, Unger R, Mejia R. Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia. Medical Sciences. 2026;14(1):5.
5. Amini F, Teh JJ, Tan CK, et al. A Pilot Randomized Controlled Trial Evaluating the Efficacy of an Exosome-Containing Plant Extract Formulation for Treating Male Alopecia. Life (Basel). 2025;15(3):500.
6. Dhaliwal NK, Moothathamby T, Sokhal BS, Gkini MA. The Use of Microneedling With Exosomes in Dermatology: A Systematic Review. J Cosmet Dermatol. 2026;25(4):e70881.
7. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993;28(5 Pt 1):755-763.
8. Garza LA, Yang CC, Zhao T, et al. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest. 2011;121(2):613-622.
9. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2).
10. Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls Publishing. Updated May 1, 2024.
11. Karakoyun Ö, Ayhan E, Yıldız İ. Retrospective Review of 2,851 Female Patients With Telogen Effluvium. J Cosmet Dermatol. 2025;24(2):e70037.
12. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-189.
13. American Academy of Dermatology. Hair loss: Diagnosis and treatment; and What is male pattern hair loss, and can it be treated? aad.org
14. International Society of Hair Restoration Surgery. 2025 Practice Census Results. ishrs.org
15. U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019. fda.gov